(MENAFN- GlobeNewsWire - Nasdaq) PDX opportunities center on precision oncology, immunotherapy testing, humanized models, CRO services and co-clinical trials, with digital tumor data and live imaging gaining traction.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Patient Derived Xenograft (PDX) Models Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Patient-Derived Xenograft Models Market to Reach $0.92 Billion by 2030 as Precision Oncology Research Expands
The global patient-derived xenograft (PDX) models market is experiencing rapid growth as pharmaceutical companies, biotechnology firms and research institutions increase their use of advanced preclinical cancer models. The market is projected to grow from $0.47 billion in 2025 to $0.54 billion in 2026, representing a compound annual growth rate (CAGR) of 15.8%.
Historic market growth has been supported by the limited predictive capabilities of traditional cell-line models, increasing cancer research initiatives and continued reliance on animal models for drug testing. Demand has also benefited from the expansion of translational oncology studies and stronger collaboration among academic institutions, pharmaceutical companies and biotechnology researchers.
The patient-derived xenograft models market is forecast to reach $0.92 billion by 2030, expanding at a CAGR of 14%. Key growth drivers include the rising adoption of PDX models in precision medicine, greater investment in humanized mouse and rat models, and the expansion of co-clinical trial programs. Contract research organizations are also broadening their PDX model services as drug developers seek specialized resources for evaluating immunotherapies, targeted therapies and other oncology treatments.
Major patient-derived xenograft models market trends include the increasing use of PDX models in preclinical drug development and personalized cancer research. Researchers are integrating digital platforms for tumor data management while expanding the use of humanized and genetically modified models. Co-clinical trials that apply PDX models alongside patient studies are also gaining attention for their potential to improve treatment selection and accelerate oncology research.
Growing demand for personalized medicine is expected to remain a significant market catalyst. Advances in genomic research are enabling healthcare providers and drug developers to select therapies based on individual tumor characteristics, supporting more precise treatment strategies. PDX models contribute to this process by allowing researchers to assess tumor responses and evaluate potential therapies before or during clinical decision-making.
Momentum in personalized healthcare is reflected in the increasing number of targeted treatment approvals. In February 2024, the Personalized Medicine Coalition reported that the US Food and Drug Administration approved 16 new personalized treatments for rare diseases during 2023, compared with six approvals in 2022. This broader focus on individualized treatment is strengthening demand for research platforms capable of supporting patient-specific oncology studies.
Innovation in imaging and model development is further enhancing the value of patient-derived xenograft models. In March 2024, InVitro Research Solutions Private Limited launched an orthotopic human glioblastoma model in NSG-SGM3 mice using patient-derived xenografts and in vivo bioluminescence imaging. The platform enables noninvasive, real-time monitoring of tumor growth, metastasis and treatment response, supporting research into targeted therapies and immunotherapies for aggressive brain cancer.
Strategic acquisitions are also shaping the competitive landscape. In October 2024, Merck & Co., Inc. acquired Modifi Biosciences, Inc. for $1.3 billion. The transaction supports Merck's oncology strategy by incorporating Modifi Biosciences' research assets, preclinical drug candidates and PDX model data. The acquired capabilities are expected to contribute to the development of therapies targeting cancers associated with DNA repair deficiencies.
North America was the largest region in the patient-derived xenograft models market in 2025, supported by its established pharmaceutical sector, advanced oncology research infrastructure and investment in precision medicine. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
Markets Covered:
1) By Type: Mice Models; Rat Models
2) By Technique: Heterotopic Implantation; Orthotropic Implantation
3) By Tumor Type: Gastrointestinal Tumor Models; Lung Tumor Models; Hematological Tumor Models; Gynecological Tumor Models; Respiratory Tumor Models; Urological Tumor Models; Other Tumor Models
4) By Application: Preclinical Drug Development; Precision Medicine; Co-Clinical Trials; Basic Cancer Research
5) By End-User: Academic And Research Organizations; Contract Research Organizations; Pharmaceutical And Biotechnological Companies; Other End-Users
Subsegments:
1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice); Humanized Mice Models; Genetically Modified Mice Models
2) By Rat Models: Immunodeficient Rat Models; Humanized Rat Models; Genetically Modified Rat Models
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment